EC conducts surprise antitrust inspections
The EC has been knocking on the doors of pharmaceutical companies to conduct surprise inspections; the agency will be looking specifically for signs of anticompetitive behaviour.
The EC has been knocking on the doors of pharmaceutical companies to conduct surprise inspections; the agency will be looking specifically for signs of anticompetitive behaviour. A memo released by the EC said: "The EC has reason to believe that the provisions of the EC Treaty prohibiting restrictive business practices and/or abuse of a dominant market position (Articles 81 and 82) may have been infringed."
The EC has been watching the pharma industry for signs of anticompetitive behaviour for more than a year. In January 2008, the EC launched a sector enquiry after a significant decline in FDA drug approvals; in particular there was concern that large pharma companies were blocking market entry of generic products. This fear was confirmed in a final report released in July 2009. In response, the EC said it would intensify its scrutiny of the pharma sector and monitor settlements between originator and generic drug companies.
The latest inspections, which were conducted on 6 October, are the first step in the investigations and the EC has stressed that such inspections do "not mean that the companies are guilty".
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
